Compare
ImmunityBio, Inc. vs Century Therapeutics, Inc. vs Atara Biotherapeutics, Inc. vs Monte Rosa Therapeutics, Inc.
| Latest fiscal year | ImmunityBio, Inc. IBRX | Century Therapeutics, Inc. IPSC | Atara Biotherapeutics, Inc. ATRA | Monte Rosa Therapeutics, Inc. GLUE |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $113.29M | $109.16M | $120.77M | $123.67M |
| Revenue growth (YoY) | +668.3% | n/m | -6.3% | +63.5% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | -226.0% | -15.8% | 29.7% | -43.8% |
| Net margin | -310.2% | -8.8% | 27.1% | -31.2% |
| Net income | -$351.40M | -$9.58M | $32.69M | -$38.63M |
| EPS (Diluted) | -$0.38 | -$0.14 | $2.57 | n/a |
| Operating cash flow | -$304.94M | -$103.88M | -$50.94M | -$22.80M |
| Free cash flow | -$308.78M | -$104.72M | -$50.94M | -$27.50M |
| Cash & equivalents | $88.33M | $61.85M | $8.48M | $129.88M |
| Total assets | $501.90M | $223.70M | $20.23M | $448.66M |
| Total liabilities | $1.00B | $64.77M | $58.74M | $215.60M |
| Shareholders' equity | -$500.47M | $158.94M | -$38.50M | $233.06M |
| Return on year-end equity | n/a | -6.0% | n/a | -16.6% |
| Shares outstanding | 1.01B | 87.52M | 7.32M | 65.54M |
Revenue, most recent five fiscal years
| Fiscal year | ImmunityBio, Inc. | Century Therapeutics, Inc. | Atara Biotherapeutics, Inc. | Monte Rosa Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $113.29M Ended 2025-12-31 | $109.16M Ended 2025-12-31 | $120.77M Ended 2025-12-31 | $123.67M Ended 2025-12-31 |
| 1 year earlier | $14.74M Ended 2024-12-31 | $6.59M Ended 2024-12-31 | $128.94M Ended 2024-12-31 | $75.62M Ended 2024-12-31 |
| 2 years earlier | $622.0K Ended 2023-12-31 | $2.23M Ended 2023-12-31 | $8.57M Ended 2023-12-31 | $0 Ended 2023-12-31 |
| 3 years earlier | $240.0K Ended 2022-12-31 | $5.20M Ended 2022-12-31 | $63.57M Ended 2022-12-31 | n/a |
| 4 years earlier | $934.0K Ended 2021-12-31 | n/a | n/a | n/a |